- QMRO Home
- Barts Cancer Institute
- Centre for Experimental Cancer Medicine
- Elevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
Browse
Administrators only